NEW YORK (GenomeWeb) – Vermillion said today that it has received a CE mark for its Overa ovarian cancer test, a second-generation version of its OVA1 test.

The company is now cleared to market Overa in the EU, and is "actively identifying global partnerships" to sell the test, Vermillion President and CEO Valerie Palmieri said in a statement.

Like OVA1, Overa is intended for triaging patients with ovarian adnexal masses as part of preoperative evaluations to determine the likelihood that a mass is cancerous.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.